CN101204365A - Implant agent treating for solid tumor - Google Patents
Implant agent treating for solid tumor Download PDFInfo
- Publication number
- CN101204365A CN101204365A CNA2007102027598A CN200710202759A CN101204365A CN 101204365 A CN101204365 A CN 101204365A CN A2007102027598 A CNA2007102027598 A CN A2007102027598A CN 200710202759 A CN200710202759 A CN 200710202759A CN 101204365 A CN101204365 A CN 101204365A
- Authority
- CN
- China
- Prior art keywords
- bortezomib
- cancer
- sustained
- acid
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 title claims abstract description 118
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 117
- 239000003795 chemical substances by application Substances 0.000 title claims description 17
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims abstract description 191
- 229960001467 bortezomib Drugs 0.000 claims abstract description 190
- 238000013268 sustained release Methods 0.000 claims abstract description 72
- 239000012730 sustained-release form Substances 0.000 claims abstract description 72
- 230000001093 anti-cancer Effects 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 9
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract description 8
- 206010038038 rectal cancer Diseases 0.000 claims abstract description 8
- 201000001275 rectum cancer Diseases 0.000 claims abstract description 8
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 7
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 7
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 7
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 7
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 7
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims abstract description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 5
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 5
- 201000000849 skin cancer Diseases 0.000 claims abstract description 4
- 201000000274 Carcinosarcoma Diseases 0.000 claims abstract description 3
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 3
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 3
- 210000004907 gland Anatomy 0.000 claims abstract description 3
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 3
- 210000001165 lymph node Anatomy 0.000 claims abstract description 3
- 210000004877 mucosa Anatomy 0.000 claims abstract description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 129
- 229920001577 copolymer Polymers 0.000 claims description 65
- 239000004626 polylactic acid Substances 0.000 claims description 59
- 229960004275 glycolic acid Drugs 0.000 claims description 51
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 51
- 238000002347 injection Methods 0.000 claims description 45
- 239000007924 injection Substances 0.000 claims description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 34
- 229930195725 Mannitol Natural products 0.000 claims description 32
- 239000000594 mannitol Substances 0.000 claims description 32
- 235000010355 mannitol Nutrition 0.000 claims description 32
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims description 31
- 229950004403 polifeprosan Drugs 0.000 claims description 31
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 20
- 229920000305 Nylon 6,10 Polymers 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 229920000954 Polyglycolide Polymers 0.000 claims description 11
- 239000004633 polyglycolic acid Substances 0.000 claims description 11
- 238000002513 implantation Methods 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 201000001514 prostate carcinoma Diseases 0.000 claims description 6
- 201000010174 renal carcinoma Diseases 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 229920002101 Chitin Polymers 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 4
- -1 chrondroitin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 37
- 238000000034 method Methods 0.000 abstract description 28
- 229920000642 polymer Polymers 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 201000007270 liver cancer Diseases 0.000 abstract description 4
- 208000014018 liver neoplasm Diseases 0.000 abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract 3
- 229960005243 carmustine Drugs 0.000 abstract 3
- 230000001988 toxicity Effects 0.000 abstract 2
- 231100000419 toxicity Toxicity 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 abstract 1
- GJBRTCPWCKRSTQ-UHFFFAOYSA-N decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.OC(=O)CCCCCCCCC(O)=O GJBRTCPWCKRSTQ-UHFFFAOYSA-N 0.000 description 27
- 229940079593 drug Drugs 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- 239000003960 organic solvent Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 229920002732 Polyanhydride Polymers 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000002131 composite material Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 230000005760 tumorsuppression Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000514745 Mactra Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001558 organosilicon polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.
Description
(1) technical field
The present invention relates to a kind of sustained-release implant for the treatment of entity tumor, belong to technical field of pharmaceuticals.
(2) background technology
Though the research about cancer has obtained bigger progress, its mortality rate still occupies the prostatitis of the various common causes of the death.Up-to-date data show that China had 3,000,000 people to die from cancer in 2006.Cancer morbidity rises year by year and is rejuvenation trend, has data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, and mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Estimate that the year two thousand twenty China will have 4,000,000 people to die from cancer therefore every year, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
In recent years, bortezomib is used as one of treatment multiple myeloma choice drug.The effect that is used for the treatment of other tumor separately is unclear.Though unite some tumors may be had certain effect by tool, limited its clinical practice by the caused whole body toxic and side effects of conventional route administration with other anticarcinogen.
(3) summary of the invention
Based on above examination to prior art, the present invention compares other tumor, found that bortezomib has comparatively significantly action effect to entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer and rectal cancer.Discover that further the bortezomib local sustained release also has good therapeutical effect to the outer entity tumor of other craniums such as thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of entity tumor.
The present invention treats the sustained-release implant of entity tumor, it is characterized in that this sustained-release implant contains the bortezomib of effective anticancer (Bortezomib, ten thousand Mactra sulcatria Deshayess or Velcade), slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) bortezomib 0.1%-60%
(2) slow-release auxiliary material 40%-99%
(3) slow release regulator 0-15%
Slow-release auxiliary material comprises one of following or its combination:
(1) biocompatibility polymer, comprise biodegradable or biological nondegradable polymer and composition thereof or copolymer, (2) water-soluble low-molecular chemical compound is or/and (3) are used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Above-mentioned biodegradable polymer comprises natural and/or synthetic polymer.Synthetic polymer as, but be not limited to polyanhydrides, polyhydroxy acid, polyester (polyesters), polyamide (polyamides), poe (polyorthoesters), polyphosphazene (polyphosphazenes), to carboxy phenyl propane (p-CPP), decanedioic acid (sebacic acid), poly-(L-lactide-co-etherophosphoric acid (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)), polifeprosan (to the copolymer of carboxy phenyl propane and decanedioic acid) etc.; Natural polymer as, but be not limited to, protein and polysaccharide comprise hyaluronic acid, collagen protein, chrondroitin, gelatin, albumin etc.
Above-mentioned polyanhydrides can be selected for use, but is not limited to, fragrant polyanhydride, aliphatic polyanhydride; Wherein fragrant polyanhydride will be separated slower, the fusing point height, and dissolubility is low in the organic solvent, however the copolymer of fragrant polyanhydride and aliphatic polyanhydride is comparatively desirable (United States Patent (USP) 4757128) but.Representative wherein is polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP) and decanedioic acid (SA)), and is fragrant polyanhydride to carboxy phenyl propane, and decanedioic acid then is the copolymer of an aromatic diacid and a fat diacid.The copolymer of available other fragrance or aliphatic polyanhydride has a detailed description in other United States Patent (USP) that (US 4857311; 4888176; 4789724).
Copolymer, polifeprosan, the ethylene vinyl acetate copolymer of the preferred polylactic acid of slow-release auxiliary material, polyglycolic acid and hydroxyacetic acid; The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
Above-mentioned polyhydroxy acid can be selected for use, but is not limited to, the copolymer (PLGA) of mixture, glycolic and the hydroxy carboxylic acid of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and polyglycolic acid; When PLA and PLGA mixing, its content percentage by weight is respectively 0.1-99.9% and 99.9-0.1%.The molecular weight of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50,000 is preferred, with 10,000-20,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50,000 is preferred, with 10,000-20,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 1000-100,000, but with 10,000-50,000 is preferred; With 10,000-20,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 5000 to 10000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 20000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 5000 to 10000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.
The nondegradable polymer of above-mentioned biology comprises, but be not limited to: organosilicon polymer, ethylene vinyl acetate copolymer (Ethelene-vinyl acetate copolymer, EVAc), polyacrylonitrile (polyacrylonitriles), polyurethanes (polyurethanes) and polyphosphazene (polyphosphazenes) etc.Compositions can discharge effective ingredient by the mode of direct diffusion.
For regulating other characteristic of drug releasing rate or change anti-cancer sustained-released implantation agent of the present invention, can change the monomer component of polymer or the composition and the proportioning of molecular weight, interpolation or adjusting slow-release auxiliary material, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar and salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt and sodium salt etc.
The used slow-release auxiliary material of sustained-release implant of the present invention can be any or multiple material in the above-mentioned slow-release auxiliary material, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or decanedioic acid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLGA, glycolic and hydroxy carboxylic acid, decanedioic acid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Slow-release auxiliary material has a detailed description in " slow-release auxiliary material complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor).In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some slow-release auxiliary material.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above slow-release auxiliary material has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned slow-release auxiliary material, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
Decanedioic acid (SA) copolymer), a kind of or its combination in ethylene vinyl acetate copolymer (EVAc), xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin and the albumin therefore, slow-release auxiliary material of the present invention mainly is selected from the copolymer (PLGA), polifeprosan of polylactic acid (PLA), polyglycolic acid and hydroxyacetic acid (to carboxy phenyl propane (p-CPP):.Wherein the molecular weight peak value of polylactic acid (PLA) is 5000-15000,10000-20000,20000-35000 or 30000-50000; The molecular weight peak value of the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA) is 5000-15000,15000-35000,35000-45000 or 45000-80000; The percentage by weight of polyglycolic acid and hydroxyacetic acid is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40; Polifeprosan (to carboxy phenyl propane (p-CPP): the percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) decanedioic acid (SA) copolymer) is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40.
Characteristics of the present invention are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other slow-release auxiliary material.The slow-release auxiliary material of adding is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Slow-release auxiliary material also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned slow-release auxiliary material is applicable to the compositions that contains or do not contain additive
For regulating other characteristic of drug releasing rate or change Anticarcinogenic internal implant agent of the present invention, can change the monomer component of polymer or the composition and the proportioning of molecular weight, interpolation or adjusting slow-release auxiliary material, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar and salt etc.Wherein sugar can be but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt and sodium salt etc.
The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.01-100 milligram/patient, is ideal with 1-50 milligram/patient, with 2-30 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of compositions can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.
Each component and the weight percentage in compositions thereof are preferred one of following in the sustained-release implant:
(A) polylactic acid of the bortezomib of 1%-5% and 95%-99%;
(B) polylactic acid of the bortezomib of 5%-10% and 90%-95%;
(C) polylactic acid of the bortezomib of 10%-15% and 85%-90%;
(D) polylactic acid of the bortezomib of 15%-25% and 75%-85%;
(E) polylactic acid of the bortezomib of 25%-40% and 60%-75%;
(F) copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid;
(G) copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid;
(H) copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid;
(I) copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid;
(J) polifeprosan of the bortezomib of 5%-15% and 85%-95%; Or
(K) polifeprosan of the bortezomib of 15%-35% and 65%-85%.
Each component and the weight percentage in compositions thereof are one of further preferred following in the sustained-release implant:
(A) mannitol of the polylactic acid of the bortezomib of 1%-5% and 85%-98% and 0.5%-15%;
(B) sorbitol of the polylactic acid of the bortezomib of 5%-10% and 90%-95% and 0.5%-10%;
(C) sodium chloride of the polylactic acid of the bortezomib of 10%-15% and 85%-90% and 0.5%-10%;
(D) mannitol of the polylactic acid of the bortezomib of 15%-25% and 75%-85% and 0.25%-5%;
(E) sorbitol of the polylactic acid 0.1%-8% of the bortezomib of 25%-40% and 60%-75%;
(F) mannitol of the copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(G) sorbitol of the copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(H) sodium chloride of the copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(I) mannitol of the copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
(J) mannitol of the polifeprosan of the bortezomib of 5%-15% and 85%-95% and 1%-5%; Or
(K) mannitol of the polifeprosan of the bortezomib of 15%-35% and 65%-85% and 0.25%-7.5%.
Sustained-release implant is used for the treatment of entity tumor, comprise the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, tumor of head and neck and come from gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes, former or cancer, sarcoma or the carcinosarcoma of secondary.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Because anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, said composition can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer composition of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Test one, bortezomib are to the inhibitory action of growth of tumour cell.
Be the inhibitory action of checking bortezomib to other growth of tumour cell, this test is added to bortezomib (15ug/ml) in 24 hours the various tumor cells of In vitro culture (table 1), continue to cultivate after 48 hours the counting cells sum and calculates its suppression ratio to growth of tumour cell (%).
The suppression ratio of growth of tumour cell (%)=((cellular control unit number-test group cell number)/cellular control unit number) * 100%
Table 1
| Tumor cell | Suppression ratio (%) |
| Hepatocarcinoma | 90 |
| Pulmonary carcinoma | 82 |
| The esophageal carcinoma | 88 |
| Gastric cancer | 72 |
| Breast carcinoma | 76 |
| Cancer of pancreas | 86 |
| Thyroid carcinoma | 84 |
| Nasopharyngeal carcinoma | 80 |
| Ovarian cancer | 78 |
| Carcinoma of endometrium | 72 |
| Cervical cancer | 80 |
| Renal carcinoma | 88 |
| Carcinoma of prostate | 78 |
| Bladder cancer | 80 |
| Colon cancer | 82 |
| Rectal cancer | 82 |
| Skin carcinoma | 82 |
| Carcinoma of testis | 80 |
The result of test one shows that compare with matched group, bortezomib all has obvious inhibitory action (P＜0.05) to the examination growth of tumor, and is wherein right.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of entity tumor provides new selection.
The sustained-release implant that contains bortezomib can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing of implanting.
The preparation method of sustained-release implant of the present invention is as follows:
The slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
Adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement.
Remove organic solvent.Vacuum drying or cold drying all can.
Dried solid composite is made different shape as required.
Ray sterilizing after the packing (roentgendosis is different because of volume) is standby.Also available other method sterilization.
(4) specific embodiment
Embodiment one,
The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 10000-20000) of (90mg) of will weighing is put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 10 milligrams of bortezomibs, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% bortezomib.The drug release time of this sustained-release implant in external normal saline is 15-20 days, is 25-30 days at the subcutaneous drug release time of mice.
Embodiment two
Make sustained-release implant by embodiment one described method, but contained anticancer effective component is one of following:
(A) 1% bortezomib and and 99% polylactic acid;
(B) 5% bortezomib and and 95% polylactic acid;
(C) 10% bortezomib and 90% polylactic acid;
(D) 15% bortezomib and 85% polylactic acid;
(E) 20% bortezomib and 80% polylactic acid.
Embodiment three
(molecular weight is the PLGA of 15000-30000 to the slow-release auxiliary material of (85mg) of will weighing, 50: 50) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add the 15mg bortezomib, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 15% bortezomib.The drug release time of this sustained-release implant in external normal saline is 14-24 days, is 20-28 days at the subcutaneous drug release time of mice.
Embodiment four
Make sustained-release implant by embodiment three described methods, contained anticancer effective component that different is is one of following:
(1) copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid;
(2) copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid;
(3) copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid;
(4) copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid;
The copolymer of (5) 5% bortezomib and 95% glycolic and hydroxyacetic acid;
The copolymer of (6) 10% bortezomib and 90% glycolic and hydroxyacetic acid;
The copolymer of (7) 20% bortezomib and 80% glycolic and hydroxyacetic acid;
The copolymer of (8) 30% bortezomib and 70% glycolic and hydroxyacetic acid.
Embodiment five
(molecular weight is the PLGA of 20000-30000 to the slow-release auxiliary material of (85mg) of will weighing, 75: 25) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add 10mg bortezomib and 5mg mannitol, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% bortezomib.The drug release time of this sustained-release implant in external normal saline is 15-25 days, is 25-40 days at the subcutaneous drug release time of mice.
Embodiment six
Make sustained-release implant by embodiment five described methods, contained anticancer effective component that different is is one of following:
(1) mannitol of the copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(2) sorbitol of the copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(3) sodium chloride of the copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(4) mannitol of the copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
The copolymer of (5) 5% bortezomib and 92% glycolic and hydroxyacetic acid and 2% sodium chloride;
The copolymer of (6) 10% bortezomib and 85% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (7) 20% bortezomib and 75% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (8) 30% bortezomib and 75% glycolic and hydroxyacetic acid and 5% mannitol.
Embodiment seven
85mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 50: 50) is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg bortezomib, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% bortezomib sustained-release implant.The drug release time of this sustained-release implant in external normal saline is 15-25 days, is 25-35 days at the subcutaneous drug release time of mice.
Embodiment eight
Make sustained-release implant by embodiment seven described methods, that contained anticancer effective component is is one of following but different is:
(1) polifeprosan of the bortezomib of 1%-15% and 85%-95%;
(2) polifeprosan of the bortezomib of 15%-35% and 65%-85%;
(3) 5% bortezomib and 95% polifeprosan;
(4) 10% bortezomib and 90% polifeprosan;
(5) 15% bortezomib and the polifeprosan of 85%-95%;
(6) 20% bortezomib and 80% polifeprosan.
Embodiment nine
80mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) and 5mg sodium chloride are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg bortezomib, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% bortezomib sustained-release implant.The drug release time of this sustained-release implant in external normal saline is 15-25 days, is 25-35 days at the subcutaneous drug release time of mice.
Embodiment ten
Make sustained-release implant by embodiment ten described methods, that contained anticancer effective component is is one of following but different is:
(1) mannitol of the polifeprosan of the bortezomib of 5%-15% and 85%-95% and 1%-5%; Or
(2) mannitol of the polifeprosan of the bortezomib of 15%-35% and 65%-85% and 0.25%-7.5%.
Embodiment 11
85mg slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) and 10mg mannitol are put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of bortezomibs, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% bortezomib.The drug release time of this sustained-release implant in external normal saline is 18-20 days, is 20-30 days at the subcutaneous drug release time of mice.
Embodiment 12
Make sustained-release implant by embodiment 11 described methods, used slow-release auxiliary material is selected from one of following or its combination:
(A) 1% bortezomib and and 95% polylactic acid and 4% mannitol;
(B) 5% bortezomib and and 93% polylactic acid and 2% mannitol;
(C) 10% bortezomib and 85% polylactic acid and 5% mannitol;
(D) 15% bortezomib and 82% polylactic acid and 3% sodium chloride;
(E) 20% bortezomib and 78% polylactic acid and 2% sodium chloride.
Embodiment 13
Make sustained-release implant by embodiment 1 to 11 described method, used slow-release auxiliary material is selected from one of following or its combination:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,15000-35000,35000-45000 or 45000-80000 and the copolymer of hydroxyacetic acid (PLGA);
C) polifeprosan is (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer), be 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to the percentage by weight of carboxy phenyl propane (p-CPP) and decanedioic acid (SA);
On the basis of above-mentioned slow release, the present invention finds that further body is implanted into bortezomib other entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are also had good therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.Following in vivo test is used for explanation but not limitation of the present invention.
Embodiment 14, tumor are implanted into the inhibitory action of bortezomib to entity tumor
Method and step: tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, and (inoculation back the 8th day) is divided into 7 groups at random with animal, 10 every group when diameter of tumor grows to the 0.8cm left and right sides.Be normal saline group, bortezomib lumbar injection group (hereinafter to be referred as bortezomib abdominal cavity group), bortezomib local injection group (being called for short the bortezomib partial groups), high molecular polymer group (being called for short high poly-group), bortezomib sustained-release implant group with (5% group, 10% group of the made sustained-release implant of embodiment four, with 20% group, be called for short implant 5%, implant 10%, implant 20%).With 70% alcohol disinfecting tumor surface skin, selection is apart from tumor lower edge 1cm place, cut off the long otch of 1mm, with puncture needle with in the bortezomib implant implantation tumour tissue, not pastille high molecular polymer, bortezomib implant 5%, bortezomib implant 10%, bortezomib implant 20%.Sew up the incision and prevent that implant from spilling.Put to death animal in 15 days with vernier caliper measurement tumor size after the implant embedding in per 3 days, the back of weighing is complete peels off tumor and claims tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 15 tumors are implanted into the tumor-inhibiting action of bortezomib spit of fland sustained-release implant to Mice Bearing Lewis Lung Cancer
Check the tumor-inhibiting action of bortezomib sustained-release implant according to embodiment 14 described methods and step to Mice Bearing Lewis Lung Cancer.Used implant adjuvant is PLGA (molecular weight is 15000-30000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50), is derived from embodiment four.The bortezomib implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Bortezomib implant tumor control rate is respectively 43%, 78%, 92%, compares with bortezomib local injection group, and the P value is all less than 0.001.Repeated experiments: tumor control rate is respectively 44%, 76%, 90%, compares with the local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and bortezomib local injection group and normal saline group comparison of tumor suppression ratio are 16% and 8.5%, and repeated experiments: tumor control rate is 11.8% and 11.2%.The tumour inhibiting rate of bortezomib implant obviously surpasses bortezomib lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 16 tumors are implanted into the tumor-inhibiting action of bortezomib sustained-release implant to mouse breast cancer
Check the tumor-inhibiting action of bortezomib sustained-release implant to mouse breast cancer according to embodiment 14 described methods and step, used implant is from embodiment one.Experimental result shows that the tumor control rate of 1%, 10% and 25% bortezomib implant is respectively 37%, 70%, 90%, compares with bortezomib local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 36%, 77%, 92%, compares with bortezomib local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 14% and 10%, and repeated experiments: tumor control rate is 13% and 8%.The tumour inhibiting rate of bortezomib implant obviously surpasses bortezomib lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 17 tumors are implanted into the tumor-inhibiting action of bortezomib sustained-release implant to rat liver cancer
Check the tumor-inhibiting action of bortezomib sustained-release implant according to embodiment 15 described methods and step to rat liver cancer, used implant is 5%, 10% and 20% polifeprosan (percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) is 50: 50), from embodiment eight.The bortezomib implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Bortezomib implant tumor control rate is respectively 50%, 66%, 84%, compares with bortezomib local injection group, and low dose group P value equals 0.001, and middle and high dosage group P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 47%, 70%, 82%, compares with bortezomib local injection group, and low dose group P value is less than 0.05, and middle and high dosage group P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and bortezomib local injection group and normal saline group comparison of tumor suppression ratio are 30% and 20%, and repeated experiments: tumor control rate is 27% and 20%.The tumour inhibiting rate of bortezomib implant obviously surpasses bortezomib lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 18 tumors are implanted into the tumor-inhibiting action of bortezomib sustained-release implant to the mice esophageal carcinoma
Check the tumor-inhibiting action of bortezomib sustained-release implant to the mice esophageal carcinoma according to embodiment 15 described methods and step, used implant is selected from embodiment six.The bortezomib implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Bortezomib implant tumor control rate is respectively 45%, 64%, 76%, compares with bortezomib local injection group, and the P value is all less than 0.001.Repeated experiments finds that tumor control rate is respectively 50%, 80%, 88%, compares with bortezomib local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 13% and 5.5%, and repeated experiments shows that tumor control rate is 12% and 13%.The tumour inhibiting rate of bortezomib implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 19 tumors are implanted into the tumor-inhibiting action of bortezomib sustained-release implant to mouse pancreas cancer
Check the tumor-inhibiting action of bortezomib sustained-release implant to mouse pancreas cancer according to embodiment 15 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of bortezomib in sustained-release implant be 2.5%, 7.5% and the bortezomib implant of 12.5%. experimental result proof various dose implant in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Bortezomib implant tumor control rate is respectively 34%, 47%, 76%, compares with bortezomib local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 58%, 65%, 72%, compares with bortezomib local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 6.6%.Repeated experiments finds that tumor control rate is 12% and 9%.The tumour inhibiting rate of bortezomib implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of bortezomib sustained-release implant to the mice rectal cancer
Check the tumor-inhibiting action of bortezomib sustained-release implant to the mice rectal cancer according to embodiment 15 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of bortezomib in sustained-release implant is 7.5%, 15% and 25%.The bortezomib implant of experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Bortezomib implant tumor control rate is respectively 54%, 77%, 86%, compares with bortezomib local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 68%, 82%, compares with bortezomib local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Bortezomib lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 6.6%.Repeated experiments finds that tumor control rate is 12% and 9%.The tumour inhibiting rate of bortezomib implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
In addition, tumor is implanted into the bortezomib sustained-release implant other entity tumors such as gastric cancer, bladder cancer, carcinoma of testis, colon cancer, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate is also had good therapeutical effect, and its effect obviously surpasses bortezomib lumbar injection group and local injection group.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
Claims (10)
1. a sustained-release implant for the treatment of entity tumor is characterized in that this sustained-release implant contains the bortezomib of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) bortezomib 0.1%-60%
(2) slow-release auxiliary material 40%-99%
(3) slow release regulator 0-15%
Wherein,
Slow-release auxiliary material is selected from copolymer, polifeprosan, poly-(a kind of or its combination in L-lactide-co-etherophosphoric acid, poly-(the L-lactide-co-phosphoric acid propyl ester) of polylactic acid, polyglycolic acid and hydroxyacetic acid;
The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
2. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) polylactic acid of the bortezomib of 1%-5% and 95%-99%;
(B) polylactic acid of the bortezomib of 5%-10% and 90%-95%;
(C) polylactic acid of the bortezomib of 10%-15% and 85%-90%;
(D) polylactic acid of the bortezomib of 15%-25% and 75%-85%;
(E) polylactic acid of the bortezomib of 25%-40% and 60%-75%;
(F) copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid;
(G) copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid;
(H) copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid;
(I) copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid;
(J) polifeprosan of the bortezomib of 5%-15% and 85%-95%; Or
(K) polifeprosan of the bortezomib of 15%-35% and 65%-85%.
3. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) mannitol of the polylactic acid of the bortezomib of 1%-5% and 85%-98% and 0.5%-15%;
(B) sorbitol of the polylactic acid of the bortezomib of 5%-10% and 90%-95% and 0.5%-10%;
(C) sodium chloride of the polylactic acid of the bortezomib of 10%-15% and 85%-90% and 0.5%-10%;
(D) mannitol of the polylactic acid of the bortezomib of 15%-25% and 75%-85% and 0.25%-5%;
(E) sorbitol of the polylactic acid 0.1%-8% of the bortezomib of 25%-40% and 60%-75%;
(F) mannitol of the copolymer of the glycolic of the bortezomib of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(G) sorbitol of the copolymer of the glycolic of the bortezomib of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(H) sodium chloride of the copolymer of the glycolic of the bortezomib of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(I) mannitol of the copolymer of the glycolic of the bortezomib of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
(J) mannitol of the polifeprosan of the bortezomib of 5%-15% and 85%-95% and 1%-5%; Or
(K) mannitol of the polifeprosan of the bortezomib of 15%-35% and 65%-85% and 0.25%-7.5%.
4. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% bortezomib and and 99% polylactic acid;
(B) 5% bortezomib and and 95% polylactic acid;
(C) 10% bortezomib and 90% polylactic acid;
(D) 15% bortezomib and 85% polylactic acid;
(E) 20% bortezomib and 80% polylactic acid;
(F) 5% bortezomib and 95% glycolic and the copolymer of hydroxyacetic acid;
(G) 10% bortezomib and 90% glycolic and the copolymer of hydroxyacetic acid;
(H) 20% bortezomib and 80% glycolic and the copolymer of hydroxyacetic acid;
(I) 30% bortezomib and 70% glycolic and the copolymer of hydroxyacetic acid;
(J) 5% bortezomib and 95% polifeprosan; Or
(K) 15% bortezomib and 85% polifeprosan.
5. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% bortezomib and and 95% polylactic acid and 4% mannitol;
(B) 5% bortezomib and and 93% polylactic acid and 2% mannitol;
(C) 10% bortezomib and 85% polylactic acid and 5% mannitol;
(D) 15% bortezomib and 82% polylactic acid and 3% sodium chloride;
(E) 20% bortezomib and 78% polylactic acid and 2% sodium chloride;
(F) 5% bortezomib and 92% glycolic and the copolymer of hydroxyacetic acid and 2% sodium chloride;
(G) 10% bortezomib and 85% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(H) 20% bortezomib and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(I) 30% bortezomib and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(J) 5% bortezomib and 92.5% polifeprosan and 2.5% mannitol; Or
(K) 15% bortezomib and 75% polifeprosan and 10% mannitol.
6. according to the described anti-cancer sustained-released implantation agent of claim 1-5, the molecular weight peak value that it is characterized in that polylactic acid is 5000-15000,10000-20000,20000-35000 or 30000-50000.
7. according to the described anti-cancer sustained-released implantation agent of claim 1-5, the molecular weight peak value that it is characterized in that the copolymer of glycolic and hydroxyacetic acid is 5000-15000,15000-35000,35000-45000 or 45000-80000; The percentage by weight of polyglycolic acid and hydroxyacetic acid is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40.
8. according to the described anti-cancer sustained-released implantation agent of claim 1-5, it is characterized in that the percentage by weight to carboxy phenyl propane and decanedioic acid is 10: 90 in the polifeprosan (to carboxy phenyl propane-decanedioic acid copolymer), 20: 80,30: 70,40: 60,50: 50 or 60: 40.
9. the described sustained-release implant of claim 1-5 is characterized in that this sustained-release implant is slow releasing injection and solid sustained-release implant.
10. the sustained-release implant according to claim 1 is characterized in that described sustained-release implant is used to prepare the treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, tumor of head and neck and originates from the pharmaceutical preparation of cancer, sarcoma or the carcinosarcoma of gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102027598A CN101204365A (en) | 2007-11-29 | 2007-11-29 | Implant agent treating for solid tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102027598A CN101204365A (en) | 2007-11-29 | 2007-11-29 | Implant agent treating for solid tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101204365A true CN101204365A (en) | 2008-06-25 |
Family
ID=39564995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007102027598A Pending CN101204365A (en) | 2007-11-29 | 2007-11-29 | Implant agent treating for solid tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101204365A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797219A (en) * | 2010-03-26 | 2010-08-11 | 中国人民解放军第四军医大学 | Solid sustained- release implant for curing esophageal carcinoma and preparation method thereof |
| EP2812338A4 (en) * | 2012-01-24 | 2015-09-23 | Millennium Pharm Inc | Method of treatment of nasopharyngeal caner |
| WO2018108164A1 (en) * | 2016-12-16 | 2018-06-21 | 宁波宁融生物医药有限公司 | Bortezomib pharmaceutical composition and applications thereof |
| WO2019148181A1 (en) * | 2018-01-29 | 2019-08-01 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
-
2007
- 2007-11-29 CN CNA2007102027598A patent/CN101204365A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797219A (en) * | 2010-03-26 | 2010-08-11 | 中国人民解放军第四军医大学 | Solid sustained- release implant for curing esophageal carcinoma and preparation method thereof |
| EP2812338A4 (en) * | 2012-01-24 | 2015-09-23 | Millennium Pharm Inc | Method of treatment of nasopharyngeal caner |
| WO2018108164A1 (en) * | 2016-12-16 | 2018-06-21 | 宁波宁融生物医药有限公司 | Bortezomib pharmaceutical composition and applications thereof |
| CN108201622A (en) * | 2016-12-16 | 2018-06-26 | 宁波宁融生物医药有限公司 | A kind of bortezomib pharmaceutical composition and its application |
| CN110381975A (en) * | 2016-12-16 | 2019-10-25 | 宁波宁融生物医药有限公司 | A kind of bortezomib pharmaceutical composition and its application |
| WO2019148181A1 (en) * | 2018-01-29 | 2019-08-01 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN100563645C (en) | A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour | |
| CN100531712C (en) | A dasatinib slow-release implant for treating solid tumors | |
| CN1330299C (en) | Medicament composition for treating extracranial noumenal tumour | |
| CN1311817C (en) | Solid tumor treating medicine composition | |
| CN101204366A (en) | Melphalan sustained-release implant treating for solid tumor | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN101204368A (en) | Pirarubicin sustained-release implant treating for solid tumor | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN100531711C (en) | An erlotinib sustained-release implant for the treatment of solid tumors | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
| CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
| CN101176715A (en) | Gefitinib sustained-release implantation agent for curing entity tumour | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080625 |